



8888888

Examiner: Not Yet Assigned

Group Art Unit: 1614

Express Mail No.: EJ756351470US

In re Application of:

Joseph K. Agyin et al

Serial No.: 09/676,032

Filed: September 29, 2000

For: Compounds and Methods of Use
Thereof in the Treatment of Cancer

or Viral Infections

Commissioner for Patents Washington, D.C. 20231

## THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 CFR §§1.56, 1.97 and 1.98, record is being made below of documents which the Patent Office is requested to consider in connection with examination of the above-identified patent application.

As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 CFR §1.97(h), this Third Supplemental Information Disclosure Statement does not constitute an admission of any kind and specifically is not an admission that the documents listed on attached Form PTO-1449 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 CFR §1.56(b).

Copies of the cited documents are enclosed for the convenience of the Patent and Trademark Office. It is respectfully requested that the documents be carefully considered by the Examiner and made of record in the case. It is also requested that the Examiner initial the PTO-1449 Form and return a copy of the initialed form to Applicants' attorney, Dr. Rose Ann Dabek.



The present document is believed timely filed under 37 CFR §1.97(b)(3), and no fees are believed due. However, if a fee is due, the Commissioner is hereby authorized to charge payment of the fee for submission of an information disclosure statement under 37 CFR §1.97(c) to Deposit Account No. 16-2480.

Respectfully submitted,

Gloria L. Norberg

Agent for Applicant(s)
Registration No. 36,706

Date: <u>July 18, 2001</u>

Akin, Gump, Strauss, Hauer & Feld, L.L.P. 816 Congress Avenue, Suite 1900 Austin, Texas 78701 (512) 499-6200